Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.16MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jonathan C. Javitt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 2.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.51
Financials
Revenue
$1.16M+378.9%Net Income
$-2.17MEBITDA
$-1.87MFree Cash Flow
$-6.71MEPS (diluted)
$-0.05Shares Outstanding (diluted)
43.17M+2185.4%Operating Expenses
$8.37MCash & Debt
$19.82MReturn of Capital
$0.00Revenue by Segment (annual)
$854.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-28.62M | $-1.34 |
| 2024 | $0.00 | $-25.13M | $-2.39 |
| 2023 | $0.00 | $-30.15M | $-3.98 |
| 2022 | $0.00 | $-39.75M | $-0.60 |
| 2021 | $0.00 | $-93.06M | $-7.44 |
| 2020 | $0.00 | $-51.78M | $-1.51 |
| 2019 | $0.00 | $408.4K | $0.80 |
| 2018 | $0.00 | $66.1K | $0.07 |
| 2017 | $0.00 | $-105.0K | $-0.12 |
Valuation
NRXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
65+30.00%Social Signal Score
Mentions (19)
- Newsmarketbeat.com·5d ago·Negative
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call NRx Pharmaceuticals NASDAQ: NRXP reported higher third-quarter patient revenue and a narrower net loss, while outlining plans to commercialize its first approved drug and advance experimental treatments for depression and other conditions.
View source ↗ - Newsglobenewswire.com·5d ago·Negative
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update FDA approved the Company's first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force
View source ↗ - Newszacks.com·6d ago·Negative
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.18 per share a year ago.
View source ↗ - Newsglobenewswire.com·11d ago·Negative
…egins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018.
View source ↗ - Newsseekingalpha.com·23d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
View source ↗ - Newsmarketbeat.com·23d ago·Negative
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection NRx Pharmaceuticals NASDAQ: NRXP said the U.S. Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine injection, marking the company's first approved product and its transition from a development-stage company to a commercial pharmaceutical company.
View source ↗ - Newsglobenewswire.com·23d ago·Negative
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date WILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD, and suicidality today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Preservative-Free K…
View source ↗ - Newsglobenewswire.com·34d ago·Negative
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation lots of preservative free…
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in operational military settings.
View source ↗ - Newsglobenewswire.com·68d ago·Negative
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry KETAFREE could turn NRXP's ketamine opportunity into a commercial business, provided FDA approval leads to a successful launch. NRXP's HOPE gives them clinical infrastructure, even though it still has a relatively small revenue base. That's why their bull case ultimately depends on successfully commercializing KETAFREE in the future.
View source ↗ - Newsglobenewswire.com·69d ago·Negative
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce the neurodegenerative findings of ALS in experi…
View source ↗ - Newsglobenewswire.com·72d ago·Negative
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), will be the first Interventional Psychiatry to deploy Zeta Surgical's newly FDA-cleared Zeta TMS …
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026.
View source ↗ - Newsseekingalpha.com·96d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·97d ago·Positive
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
View source ↗ - Newsmarketbeat.com·104d ago·Negative
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product's vial connector.
View source ↗
Earnings
Mon, Mar 22(in 4 months)
Consensus estimate $-0.34 per share
Typical surprise -62.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.05 vs $-0.21beat
- Mon, Aug 17$-0.44 vs $-0.11miss
- Fri, May 15$-0.04 vs $-0.05beat
- Mon, Mar 23$0.19 vs $-0.09beat
- Mon, Nov 17$-0.27 vs $-0.11miss
- Mon, Aug 18$-0.98 vs $-0.15miss
Estimates and results for NRXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRXP officers and directors.
- Bought
- $6.7m
- Sold
- $2.4m
19 trades
10 trades
- Javitt Jonathan Cboughtdirector, 10 percent owner, officer: Chairman and Chief Scientist·40,000 @ $1.17·$47k·Dec 17, 2024·filing
- Gorovitz Aaronbought
- Hurvitz Chaimbought
- Javitt Jonathan Cbought
- Javitt Jonathan Cbought
- Willard Stephen Hbought
- Van Voorhees Sethbought
- Javitt Jonathan Csold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
